One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Diversifying the Physician Workforce — From Rhetoric to Positive Action
Quinn Capers, IV, M.D.
doi : 10.1056/NEJMp2211874
Vol. 388 No. 10
Electronic Prior Authorization for Prescription Drugs — Challenges and Opportunities for Reform
Jing Luo, M.D., M.P.H., and Walid F. Gellad, M.D., M.P.H.
doi : 10.1056/NEJMp2214620
Alliance for Hippocratic Medicine v. FDA — Dobbs’s Collateral Consequences for Pharmaceutical Regulation
Patricia J. Zettler, J.D., Eli Y. Adashi, M.D., and I. Glenn Cohen, J.D.
doi : 10.1056/NEJMp2301813
Treatment Strategy for Rifampin-Susceptible Tuberculosis
Nicholas I. Paton, M.D., Christopher Cousins, M.B., Ch.B., Celina Suresh, B.Sc., Erlina Burhan, M.D., Ka Lip Chew, F.R.C.P.A., Victoria B. Dalay, M.D., Qingshu Lu, Ph.D., Tutik Kusmiati, M.D., Vincent M. Balanag, M.D., Shu Ling Lee, B.Sc., Rovina Ruslami, Ph.D., Yogesh Pokharkar, M.Sc.,
doi : 10.1056/NEJMoa2212537
Tuberculosis is usually treated with a 6-month rifampin-based regimen. Whether a strategy involving shorter initial treatment may lead to similar outcomes is unclear.
Duration of Device-Based Fever Prevention after Cardiac Arrest
Christian Hassager, M.D., D.M.Sc., Henrik Schmidt, M.D., D.M.Sc., Jacob E. Møller, M.D., D.M.Sc., Johannes Grand, M.D., Ph.D., Simon Mølstrøm, M.D., Rasmus P. Beske, M.D., Søren Boesgaard, M.D., D.M.Sc., Britt Borregaard, R.N., Ph.D., Ditte Bekker-Jensen, R.N., M.Sc., Jordi S. Dahl, M.D., Ph.D., Martin S. Frydland, M.D., Ph.D., Dan E. Høfsten, M.D., Ph.D.,
doi : 10.1056/NEJMoa2212528
Guidelines recommend active fever prevention for 72 hours after cardiac arrest. Data from randomized clinical trials of this intervention have been lacking.
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
Mrinal Gounder, M.D., Ravin Ratan, M.D., Thierry Alcindor, M.D., Patrick Schöffski, M.D., M.P.H., Winette T. van der Graaf, M.D., Ph.D., Breelyn A. Wilky, M.D., Richard F. Riedel, M.D., Allison Lim, Pharm.D., L. Mary Smith, Ph.D., Stephanie Moody, M.S., Steven Attia, D.O., Sant Chawla, M.D.,
doi : 10.1056/NEJMoa2210140
Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.
Outcomes after Critical Illness
Margaret S. Herridge, M.D., M.P.H., and Élie Azoulay, M.D., Ph.D.
doi : 10.1056/NEJMra2104669
“Hairy Kidney� in Erdheim–Chester Disease
Nityasree Srialluri, M.D., and Mohamed G. Atta, M.D.
doi : 10.1056/NEJMicm2208776
Papulopustular Rash in Behçet’s Disease
Andrea Finazzi, M.D., and Roberto Cosentini, M.D.
doi : 10.1056/NEJMicm2209759
Case 7-2023: A 70-Year-Old Man with Covid-19, Respiratory Failure, and Rashes
Michael K. Mansour, M.D., Ph.D., Joseph D. King, M.D., Steven T. Chen, M.D., M.P.H., M.H.P.Ed., Jay A. Fishman, M.D., and Rosalynn M. Nazarian, M.D.
doi : 10.1056/NEJMcpc2211369
Shortening Tuberculosis Treatment — A Strategic Retreat
Véronique Dartois, Ph.D., and Eric J. Rubin, M.D., Ph.D.
doi : 10.1056/NEJMe2300413
Temperature Management after Cardiac Arrest — All In or Fold?
Stephen Bernard, M.D., and Janet Bray, Ph.D.
doi : 10.1056/NEJMe2214973
The Climate Gap and the Color Line — Racial Health Inequities and Climate Change
Rachel Morello-Frosch, Ph.D., M.P.H., and Osagie K. Obasogie, Ph.D., J.D.
doi : 10.1056/NEJMe2214973
Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis
doi : 10.1056/NEJMc2216309
